PDPs are equipped to help prevent and respond to urgent emerging and future health threats

The capabilities of PDPs are not limited to poverty-related diseases. PDPs have mobilized to contribute to the global response to the COVID-19 pandemic by developing vaccine and monoclonal antibody candidates, providing chemical libraries to be tested for potential efficacy against SARS-CoV-2, and applying drug discovery techniques to aid in COVID-19 product research. PDPs are staging large-scale adaptive platform trials in Africa, connecting scientists across the continent for therapeutic testing, and convening novel partnerships to accelerate the development, production, and broad, equitable access to COVID-19 tests, treatments, and vaccines that meet the needs of resource-limited contexts. PDPs are also developing products and coalitions to address looming health threats, such as antimicrobial resistance